Royalty Pharma plc Quarterly Income Statements Chart
Quarterly
|
Annual
Royalty Pharma plc Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| income and other revenues | |||||||||||||||||||||
| income from financial royalty assets | 550,418,000 | 539,490,000 | 561,845,000 | 533,166,000 | 512,865,000 | 541,546,000 | 523,065,000 | 508,657,000 | 501,345,000 | 664,687,000 | 546,541,000 | 551,682,000 | 515,350,000 | 511,523,000 | 526,212,000 | 505,832,000 | 503,414,000 | 529,625,000 | 524,439,000 | 498,515,000 | 474,177,000 |
| other royalty income and revenues | 28,247,000 | 28,757,000 | 31,796,000 | 31,524,000 | 24,402,000 | 26,432,000 | |||||||||||||||
| total income and other revenues | 578,665,000 | 568,247,000 | 593,641,000 | 564,690,000 | 537,267,000 | 567,978,000 | 596,068,000 | 536,313,000 | 538,202,000 | 683,971,000 | 565,748,000 | 573,463,000 | 535,955,000 | 562,049,000 | 575,700,000 | 585,773,000 | 554,963,000 | 573,027,000 | 572,143,000 | 538,399,000 | 510,932,000 |
| operating (income)/expense | |||||||||||||||||||||
| benefit from changes in expected cash flows from financial royalty assets | -203,938,000 | -127,140,000 | 164,036,000 | -227,604,000 | 212,429,000 | 583,600,000 | -76,513,000 | 277,137,000 | 241,228,000 | 118,804,000 | 308,848,000 | 305,061,000 | 105,714,000 | 184,621,000 | 266,505,000 | 137,837,000 | -243,762,000 | 292,262,000 | 129,341,000 | -33,792,000 | 47,278,000 |
| benefit from credit losses on unfunded commitments | 92,535,000 | ||||||||||||||||||||
| research and development funding expense | 300,500,000 | 50,500,000 | 500,000 | 500,000 | 500,000 | 500,000 | 500,000 | 50,500,000 | 500,000 | 500,000 | 50,500,000 | 25,500,000 | 606,000 | 100,500,000 | 103,821,000 | 90,500,000 | 3,122,000 | 2,641,000 | 7,779,000 | 5,096,000 | 5,776,000 |
| general and administrative expenses | 179,769,000 | 110,705,000 | 67,591,000 | 56,720,000 | 54,708,000 | 57,652,000 | 59,185,000 | 57,234,000 | 47,634,000 | 85,695,000 | 73,228,000 | 50,692,000 | 51,843,000 | 51,540,000 | 46,161,000 | 48,588,000 | 44,921,000 | 43,156,000 | 50,119,000 | 50,732,000 | 42,799,000 |
| total operating expense | 368,866,000 | 34,065,000 | |||||||||||||||||||
| operating income | 209,799,000 | 361,514,000 | 735,074,000 | 269,630,000 | 612,896,000 | 151,442,000 | 248,840,000 | 478,972,000 | -482,655,000 | 192,210,000 | 377,792,000 | 219,718,000 | 153,417,000 | 303,052,000 | 744,949,000 | 229,297,000 | 314,055,000 | 510,567,000 | 409,346,000 | ||
| yoy | -22.19% | -41.02% | 385.38% | 8.35% | -226.98% | -21.21% | -34.13% | 117.99% | -414.60% | -36.58% | -49.29% | -4.18% | -51.15% | -40.64% | 81.99% | ||||||
| qoq | -50.82% | 172.62% | 304.71% | -39.14% | -48.05% | -199.24% | -351.11% | -49.12% | 71.94% | 43.22% | -49.38% | -59.32% | 224.88% | -26.99% | -38.49% | 24.73% | |||||
| operating margin % | |||||||||||||||||||||
| other (income)/expense | |||||||||||||||||||||
| equity in (earnings)/losses of equity method investees | -2,693,000 | -6,443,000 | -31,650,000 | -10,407,000 | -1,703,000 | -397,000 | |||||||||||||||
| interest expense | 68,668,000 | 65,261,000 | 65,761,000 | 66,506,000 | 49,013,000 | 44,232,000 | 47,255,000 | 46,033,000 | 46,949,000 | 46,950,000 | 46,955,000 | 46,977,000 | 46,966,000 | 47,063,000 | 46,974,000 | 44,327,000 | 37,426,000 | 37,415,000 | 37,842,000 | 31,444,000 | 34,189,000 |
| losses on derivative financial instruments | 2,000,000 | 1,000,000 | 96,000 | 16,972,000 | |||||||||||||||||
| losses/(gains) on equity securities | 30,553,000 | 45,878,000 | 47,124,000 | 30,086,000 | 19,289,000 | ||||||||||||||||
| losses/(gains) on available for sale debt securities | 27,420,000 | 3,281,000 | 200,000 | ||||||||||||||||||
| interest income | -8,327,000 | -11,290,000 | -9,037,000 | -17,508,000 | -13,381,000 | -7,417,000 | -6,500,000 | -23,436,000 | -25,653,000 | -16,702,000 | -43,853,000 | -14,034,000 | -10,919,000 | -9,529,000 | -10,639,000 | -12,261,000 | -14,037,000 | -16,598,000 | -21,210,000 | -1,587,000 | -2,724,000 |
| other non-operating expenses/(income) | 1,543,000 | -165,250 | 1,654,000 | ||||||||||||||||||
| total other income | 119,164,000 | -69,501,000 | -102,496,000 | 70,318,000 | |||||||||||||||||
| consolidated net income before tax | 90,635,000 | 334,351,000 | 806,358,000 | 194,377,000 | 717,586,000 | 122,077,000 | 351,336,000 | 509,089,000 | -610,030,000 | 220,414,000 | 491,597,000 | 128,083,000 | 53,671,000 | 221,796,000 | 806,755,000 | 158,979,000 | 366,628,000 | 624,254,000 | 601,976,000 | ||
| income tax expense | |||||||||||||||||||||
| consolidated net income | 90,635,000 | 334,351,000 | 806,358,000 | 194,377,000 | 717,586,000 | 122,077,000 | 351,336,000 | 509,089,000 | -610,030,000 | 220,414,000 | 491,597,000 | 128,083,000 | 53,671,000 | 221,796,000 | 806,755,000 | 158,979,000 | 366,628,000 | 624,254,000 | 601,976,000 | ||
| net income attributable to non-controlling interests | 60,459,000 | 126,137,000 | 262,371,000 | 92,373,000 | 223,246,000 | 49,963,000 | 123,711,000 | 168,334,000 | -153,946,000 | 77,763,000 | 187,093,000 | 76,322,000 | |||||||||
| net income attributable to royalty pharma plc | 30,176,000 | 238,349,000 | 208,214,000 | 543,987,000 | 102,004,000 | 4,778,000 | 494,340,000 | 72,114,000 | 227,625,000 | 340,755,000 | -456,084,000 | 142,651,000 | 304,504,000 | 51,761,000 | |||||||
| earnings per class a ordinary share: | |||||||||||||||||||||
| basic | 70 | 550 | 470 | 1,220 | 230 | 10 | 1,110 | 160 | 510 | 760 | -1,040 | 320 | 700 | 120 | 240 | 1,080 | 180 | 440 | 790 | ||
| diluted | 70 | 550 | 470 | 1,210 | 230 | 10 | 1,100 | 160 | 500 | 760 | -1,040 | 320 | 700 | 120 | 240 | 1,080 | 180 | 440 | 790 | ||
| weighted-average class a ordinary shares outstanding: | |||||||||||||||||||||
| basic | 423,514,000 | 435,480,000 | 448,185,000 | 447,628,000 | 451,020,000 | 448,623,000 | 447,601,000 | 448,439,000 | 450,405,000 | 445,612,000 | 437,963,000 | 439,293,000 | 436,318,000 | 433,956,000 | 414,794,000 | 428,230,000 | 409,344,000 | 389,760,000 | 375,444,000 | 369,999,000 | 353,979 |
| diluted | 562,298,000 | 578,102,000 | 594,108,000 | 592,726,000 | 596,912,000 | 597,479,000 | 602,900,000 | 601,138,000 | 605,860,000 | 607,251,000 | 437,972,000 | 607,226,000 | 607,214,000 | 607,201,000 | 414,802,000 | 607,174,000 | 607,163,000 | 607,148,000 | 375,455,000 | 370,002,000 | 353,980 |
| operating income/ | 534,182,000 | ||||||||||||||||||||
| other non-operating expenses | 3,062,000 | ||||||||||||||||||||
| total other income/(income) | 100,749,000 | -25,812,000 | 29,365,000 | 99,746,000 | 81,256,000 | ||||||||||||||||
| consolidated net income/(loss) before tax | 433,433,000 | ||||||||||||||||||||
| consolidated net income/ | 433,433,000 | ||||||||||||||||||||
| net income/(loss) attributable to non-controlling interests | 195,084,000 | ||||||||||||||||||||
| total operating (income)/expense | 184,751,250 | -170,384,000 | -189,986,000 | ||||||||||||||||||
| (gains)/losses on derivative financial instruments | -750,000 | -3,000,000 | 980,000 | -25,785,000 | -71,805,000 | ||||||||||||||||
| gains on equity securities | -20,363,750 | -50,849,000 | |||||||||||||||||||
| gains on available for sale debt securities | -25,975,000 | -57,680,000 | -46,420,000 | -30,625,000 | -7,300,000 | -82,900,000 | |||||||||||||||
| total other (income)/expense | 27,163,000 | -71,284,000 | -61,806,000 | -52,573,000 | -113,687,000 | -192,630,000 | |||||||||||||||
| operating expenses | |||||||||||||||||||||
| total operating expenses | 267,637,000 | 641,752,000 | -16,828,000 | 384,871,000 | 289,362,000 | 204,999,000 | 1,048,403,000 | 381,253,000 | 342,331,000 | 109,116,250 | 282,721,000 | 343,730,000 | 258,088,000 | 27,832,000 | 101,586,000 | ||||||
| losses/(gains) on derivative financial instruments | 8,680,000 | 700,000 | |||||||||||||||||||
| other non-operating (income)/expenses | -6,000,000 | ||||||||||||||||||||
| total other incomes/(income) | 75,253,000 | ||||||||||||||||||||
| operating (loss)/income | -73,774,000 | ||||||||||||||||||||
| other income/ | |||||||||||||||||||||
| equity in losses/(earnings) of equity method investees | 14,149,000 | -7,153,500 | 5,222,000 | 770,000 | 6,856,000 | 3,251,000 | |||||||||||||||
| gains on derivative financial instruments | -7,090,000 | ||||||||||||||||||||
| (gains)/losses on equity securities | -77,730,000 | -55,145,000 | -1,541,000 | -41,271,000 | 5,742,500 | -5,168,000 | -8,024,000 | ||||||||||||||
| other non-operating expense | 3,685,000 | 18,308,000 | 1,707,000 | 2,813,000 | 1,165,000 | 10,798,000 | 1,035,000 | 214,500 | 793,000 | ||||||||||||
| consolidated net (loss)/income before tax | -4,273,000 | ||||||||||||||||||||
| consolidated net (loss)/income | -4,273,000 | ||||||||||||||||||||
| net (loss)/income attributable to non-controlling interests | -9,051,000 | ||||||||||||||||||||
| revenue from intangible royalty assets | 238,000 | 252,000 | 202,000 | 143,000 | 288,000 | 1,073,000 | 2,537,000 | 33,586,000 | 31,654,000 | 63,406,000 | 40,127,000 | 36,061,000 | 40,404,000 | 34,550,000 | 33,445,000 | ||||||
| other royalty income | 72,765,000 | 27,404,000 | 36,655,000 | 19,141,000 | 18,919,000 | 20,708,000 | 18,068,000 | 16,940,000 | 17,834,000 | 16,535,000 | 11,422,000 | 7,341,000 | 7,300,000 | 5,334,000 | 3,310,000 | ||||||
| amortization of intangible assets | 5,670,000 | 5,796,000 | 5,796,000 | 5,733,000 | 5,671,000 | 5,796,000 | 5,796,000 | 5,733,000 | |||||||||||||
| other non-operating (income)/expense | -1,091,000 | -43,000 | -261,000 | ||||||||||||||||||
| equity in earnings of equity method investees | -34,606,000 | -737,000 | |||||||||||||||||||
| losses on equity securities | 10,818,000 | 36,162,000 | |||||||||||||||||||
| (gains)/losses on available for sale debt securities | -32,300,000 | -24,496,250 | -44,243,000 | ||||||||||||||||||
| total other (income)/expenses | -30,117,000 | -12,593,500 | -28,204,000 | -113,805,000 | |||||||||||||||||
| income and other revenues: | |||||||||||||||||||||
| total operating expenses/(income) | 158,163,000 | ||||||||||||||||||||
| unrealized gains on available for sale debt securities | -70,321,000 | ||||||||||||||||||||
| total income and revenues | |||||||||||||||||||||
| unrealized losses/(gains) on available for sale debt securities | 16,579,000 | -2,061,500 | 14,885,000 | ||||||||||||||||||
| other non-operating expense/(income) | 1,757,000 | 107,000 | 3,821,000 | 23,337,000 | |||||||||||||||||
| total other incomes | 91,635,000 | ||||||||||||||||||||
| equity in earnings of non-consolidated affiliates | -4,633,000 | -2,749,000 | -17,701,000 | ||||||||||||||||||
| net income attributable to non-controlling interest | 45,767,000 | 119,867,000 | 365,979,000 | ||||||||||||||||||
| net income attributable to controlling interest | 7,904,000 | 101,929,000 | 440,776,000 | 69,119,000 | 171,094,000 | 290,632,000 | 442,074,000 | ||||||||||||||
| other comprehensive income/ | |||||||||||||||||||||
| reclassification of loss on interest rate swaps | |||||||||||||||||||||
| unrealized (losses)/gains on available for sale debt securities | 2,143,500 | -2,575,000 | |||||||||||||||||||
| reclassification of unrealized gains on available for sale debt securities | -10,136,250 | -11,756,000 | |||||||||||||||||||
| other comprehensive (loss)/income | -7,992,750 | -14,331,000 | -7,274,000 | -10,366,000 | |||||||||||||||||
| other comprehensive (loss)/income attributable to non-controlling interest | -3,528,000 | -6,000,000 | -3,231,000 | ||||||||||||||||||
| other comprehensive (loss)/income attributable to controlling interest | -4,464,750 | -8,331,000 | -4,043,000 | ||||||||||||||||||
| comprehensive income attributable to controlling interest | 148,491,250 | 93,598,000 | 436,733,000 | 63,634,000 | 168,609,000 | 294,435,000 | 447,399,000 | ||||||||||||||
| earnings per class a ordinary share : | |||||||||||||||||||||
| basic | 70 | 550 | 470 | 1,220 | 230 | 10 | 1,110 | 160 | 510 | 760 | -1,040 | 320 | 700 | 120 | 240 | 1,080 | 180 | 440 | 790 | ||
| diluted | 70 | 550 | 470 | 1,210 | 230 | 10 | 1,100 | 160 | 500 | 760 | -1,040 | 320 | 700 | 120 | 240 | 1,080 | 180 | 440 | 790 | ||
| weighted-average class a ordinary shares outstanding : | |||||||||||||||||||||
| basic | 423,514,000 | 435,480,000 | 448,185,000 | 447,628,000 | 451,020,000 | 448,623,000 | 447,601,000 | 448,439,000 | 450,405,000 | 445,612,000 | 437,963,000 | 439,293,000 | 436,318,000 | 433,956,000 | 414,794,000 | 428,230,000 | 409,344,000 | 389,760,000 | 375,444,000 | 369,999,000 | 353,979 |
| diluted | 562,298,000 | 578,102,000 | 594,108,000 | 592,726,000 | 596,912,000 | 597,479,000 | 602,900,000 | 601,138,000 | 605,860,000 | 607,251,000 | 437,972,000 | 607,226,000 | 607,214,000 | 607,201,000 | 414,802,000 | 607,174,000 | 607,163,000 | 607,148,000 | 375,455,000 | 370,002,000 | 353,980 |
| loss/(gain) on derivative financial instruments | 1,909,000 | ||||||||||||||||||||
| gain on equity securities | -55,495,000 | ||||||||||||||||||||
| unrealized gain on available for sale debt securities | -14,015,000 | -9,115,000 | |||||||||||||||||||
| reclassification of unrealized gain on available for sale debt securities | -13,299,000 | -15,491,000 | |||||||||||||||||||
| equity in loss of non-consolidated affiliates | 1,918,000 | ||||||||||||||||||||
| unrealized loss on derivative financial instruments | 2,555,000 | 9,971,500 | 7,088,000 | ||||||||||||||||||
| loss on equity securities | 54,186,000 | ||||||||||||||||||||
| less: net income attributable to non-controlling interest | -89,860,000 | -195,534,000 | -333,622,000 | -159,902,000 | |||||||||||||||||
| comprehensive income | 58,753,000 | 166,418,000 | 298,203,000 | 449,023,000 | |||||||||||||||||
| less: other comprehensive loss/(income) attributable to non-controlling interest | 4,881,000 | ||||||||||||||||||||
| equity in (earnings)/loss of non-consolidated affiliates | -10,498,000 | -13,743,000 | -29,292,000 | ||||||||||||||||||
| unrealized (gain)/loss on equity securities | -50,238,750 | -160,226,000 | -193,895,000 | ||||||||||||||||||
| other comprehensive income | 17,827,750 | 7,571,000 | 6,949,000 | ||||||||||||||||||
| reclassification of loss on interest rate swaps included in net income | 1,016,500 | ||||||||||||||||||||
| change in unrealized movement on available for sale debt securities | 16,811,250 | 7,571,000 | 6,949,000 | ||||||||||||||||||
| less: other comprehensive income attributable to non-controlling interest | 2,191,000 | -3,768,000 | -1,624,000 | ||||||||||||||||||
| unrealized (gain)/loss on derivative contracts | -647,000 | ||||||||||||||||||||
| earnings per share of class a ordinary shares : | |||||||||||||||||||||
| basic | 0.09 | ||||||||||||||||||||
| diluted | 0.09 | ||||||||||||||||||||
| weighted-average shares of class a shares outstanding : | |||||||||||||||||||||
| basic | 423,514,000 | 435,480,000 | 448,185,000 | 447,628,000 | 451,020,000 | 448,623,000 | 447,601,000 | 448,439,000 | 450,405,000 | 445,612,000 | 437,963,000 | 439,293,000 | 436,318,000 | 433,956,000 | 414,794,000 | 428,230,000 | 409,344,000 | 389,760,000 | 375,444,000 | 369,999,000 | 353,979 |
| diluted | 562,298,000 | 578,102,000 | 594,108,000 | 592,726,000 | 596,912,000 | 597,479,000 | 602,900,000 | 601,138,000 | 605,860,000 | 607,251,000 | 437,972,000 | 607,226,000 | 607,214,000 | 607,201,000 | 414,802,000 | 607,174,000 | 607,163,000 | 607,148,000 | 375,455,000 | 370,002,000 | 353,980 |
We provide you with 20 years income statements for Royalty Pharma plc stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Royalty Pharma plc stock. Explore the full financial landscape of Royalty Pharma plc stock with our expertly curated income statements.
The information provided in this report about Royalty Pharma plc stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.